Cantor Fitzgerald Reiterates Overweight on Harmony Biosciences, Maintains $49 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a $49 price target.
February 23, 2024 | 5:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Harmony Biosciences and maintained a $49 price target.
The reiteration of an Overweight rating and the maintenance of a $49 price target by a reputable analyst suggests a positive outlook for Harmony Biosciences. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100